In a phase II advanced prostate and renal cancer trial using the BiAb MDX-H210 (15 μg/m2) IV and GM-CSF 5 μg/kg/day subcutaneously for 4 days repeated weekly for 6 weeks, 7 of 20 (35%) patients with prostate cancer had objective responses (>50% decline in PSA) [38]. The gene discussed is CSF2; the disease is Familial prostate cancer.